Drug Profile
GRI 1
Latest Information Update: 03 Mar 2008
Price :
$50
*
At a glance
- Originator NPS Pharmaceuticals
- Developer Janssen L.P.; NPS Pharmaceuticals
- Class Antipsychotics
- Mechanism of Action Glycine reuptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Dementia; Schizophrenia
Most Recent Events
- 09 Dec 2005 Phase-I clinical trials in Schizophrenia in USA (unspecified route)
- 20 Oct 2003 Preclinical trials in Dementia in USA (unspecified route)
- 19 Nov 2001 NPS Pharmaceuticals has received a milestone payment from Janssen in recognition of selection of a promising drug candidate